Evidence map›Paper›PMID 41024768›Full record

ArticleWorld journal of gastroenterology2025

Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer.

Ke-Ning Li, Lei-Lei Ying, Nan Du, Ying Wang, Hao-Zhe Huang, Yao-Hui Wang, Li-Chao Xu, Qing Zhao, Ge Song, Yu-Bin Hu and 4 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ke-Ning LiDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Lei-Lei YingDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Nan DuDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ying WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hao-Zhe HuangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yao-Hui WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Li-Chao XuDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Qing ZhaoDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ge SongDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yu-Bin HuDepartment of Tumor and Vascular Interventional Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China.
Wen-Tao LiDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yan YanDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Chao ChenDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xin-Hong HeDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung oligometastases from CRC after RFA plus maintenance capecitabine with RFA alone.

aimTo determine whether adding capecitabine to RFA improves prognosis compared with RFA alone.

methodsThis multicenter retrospective study included consecutive patients from two tertiary cancer centers treated for pulmonary oligometastases from CRC between 2016 and 2023. Subjects were assigned to RFA plus capecitabine (combined) or RFA alone (only RFA) groups. Primary outcomes included overall survival (OS) and progression-free survival (PFS) survival and the secondary outcome was local tumor progression (LTP). The OS, PFS, and LTP rates were compared between the two groups. In addition, prognostic factors were identified using univariate and multivariate analyses.

resultsCombination therapy (RFA + capecitabine,

conclusionRFA prolongs survival and local control in patients with CRC pulmonary oligometastases. Adjuvant capecitabine increases OS and reduces LTP compared to RFA alone, but PFS did not significantly change.

Indexed as

Antimetabolites, AntineoplasticCapecitabineColorectal NeoplasmsLung NeoplasmsRadiofrequency AblationAdultAgedCombined Modality TherapyFemaleHumansMaintenance ChemotherapyMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesAntimetabolites, AntineoplasticCapecitabineCapecitabineColorectal cancerLung oligometastasesMaintenance therapyRadiofrequency ablation

Identifiers

PMID41024768
PMCPMC12476658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.